SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-034186
Filing Date
2024-04-18
Accepted
2024-04-18 17:27:09
Documents
16
Period of Report
2024-04-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203748-8k_adial.htm   iXBRL 8-K 49415
2 AT THE MARKET OFFERING AGREEMENT, DATED APRIL 18, 2024, BY AND BETWEEN ADIAL PHA ea020374801ex1-1_adial.htm EX-1.1 207768
3 OPINION OF BLANK ROME LLP ea020374801ex5-1_adial.htm EX-5.1 11552
4 GRAPHIC ex5-1_001.jpg GRAPHIC 2510
  Complete submission text file 0001213900-24-034186.txt   505426

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adil-20240417.xsd EX-101.SCH 3024
6 XBRL LABEL FILE adil-20240417_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE adil-20240417_pre.xml EX-101.PRE 22365
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0203748-8k_adial_htm.xml XML 3589
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

IRS No.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 24855122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)